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patients who need antifungal prophylaxis. METHODS: All claims data of patients 
who received HSCT between April 2010 and September 2013 were extracted from 
the database developed by MinaCare Co., Ltd. The database contains health check-
up and claims data obtained from approximately 2.1 million members of employ-
ment-based health insurance groups and their dependents. We defined prophylactic 
use of antifungal medication as prescription of antifungal drugs for more than 14 
consecutive days concomitantly with new quinolones, SMX/TMP and/or antivirus 
drugs. RESULTS: We identified 87 patients who received HSCT in the database 
altogether, of which 50 patients were considered to have received HSCT during 
the period examined. Among this population, 33 patients received the autologous 
peripheral blood stem cell transplantation and 14 patients received the cord blood 
stem cell transplantation (CBT). The major primary diseases were malignant lym-
phoma and multiple myeloma. Among the patients who received HSCT, 47 patients 
(94%) were prescribed with at least one antifungal, whereas those receiving CBT 
or those experienced graft versus host disease (GVHD) after transplantation had 
a tendency to be prescribed antimold drugs such as Micafungin and Voriconazole. 
In addition, 35 patients (70%) were prescribed antifungals as prophylaxis, as our 
definition above. CONCLUSIONS: This is the first investigation to demonstrate the 
percentage of HSCT recipients prescribed with antifungals, and that patients who 
received CBT or experienced GVHD had greater tendency to be prescribed anti-
mold agents. In order to assess the risk factors of invasive fungal infection in HSCT 
patients, further investigation is needed.
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OBJECTIVES: Although the compounds in marijuana increase appetite, empirical 
studies have estimated that marijuana users have lower BMI and rates of obe-
sity than non-users. Failure to account for differences in behaviors and attitudes 
increases the potential for confounding, since the decision to engage in marijuana 
use is tied to such attributes. This study investigated how estimates of the effect of 
marijuana use on BMI are altered by such considerations. METHODS: Participants in 
Wave IV of the National Longitudinal Study of Adolescent Health (Add Health) were 
interviewed between 2008 and 2009 (age 24-32). Multivariate regressions estimated 
the relationship between marijuana use and BMI (kg/m2). Regressions were then 
stratified by behavioral variables, including age of onset of marijuana use, concur-
rent alcohol use, self-assessed weight status, risk-propensity, and gender. RESULTS: 
Consistent with other empirical studies, marijuana use is associated with lower BMI 
in the core model (P= 0.015). However, results change when models are stratified 
by behavioral variables. The negative association between marijuana use and BMI 
persists in individuals who drink more than once a week (P< 0.05); however, in non-
drinkers (who have tried alcohol), the magnitude and direction of the effect changes 
drastically (-0.996, p= 0.015 vs. 7.96, p= 0.007). Users who initiated use at 17 or older 
do not have lower BMI (P= 0.937). In individuals who identified as satisfactory weight 
or overweight, there is no association (P= 0.313 and P= 0.748, respectively, vs. P = 
0.005 in underweight individuals). Estimates are negative and significant in self-
identified risk-takers (P= 0.037), but not in non-risk-takers (P= 0.549 and P= 0.401). 
Results are not significant in females (P= 0.976). CONCLUSIONS: The extent to which 
marijuana use influences BMI may depend on behavioral factors. Investigation is 
required to pinpoint behavioral attributes responsible for differences in BMI among 
marijuana users. The results have implications for assessing the role of marijuana 
in strategies to address obesity.
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OBJECTIVES: Phentermine and topiramate extended-release (PHEN/TPM ER) was 
approved by the US FDA in July 2012 for chronic weight management in combina-
tion with lifestyle modifications in adults with a body mass index (BMI) of ≥ 30 or 
≥ 27kg/m2and ≥ 1 weight-related comorbidity. This interim second analysis of a 
Phase 4 post-marketing study assessed the medical appropriateness of prescribed 
PHEN/TPM ER by examining the total number of PHEN/TPM ER users, their demo-
graphics, weight-related comorbidities, and concomitant medication use over 
18 months post-approval. METHODS: Data were collected from two databases 
between 17 September 2012 and 28 February 2014; the Qsymia Certified Pharmacy 
Network (QCPN) database collected age and gender information of all patients with 
≥ 1 recorded PHEN/TPM ER prescription; the Humedica Electronic Health Record 
(HEHR) database collected age, gender, race, BMI, weight-related comorbidities, 
and concomitant medication use. . Older patients (≥ 61 years) were evaluated for 
this subanalysis. RESULTS: There were 160,853 and 5253 patients in the QCPN and 
HEHR databases, respectively. Of these, 22,579 and 649 patients from the QCPN 
and HEHR databases, respectively were ≥ 61 years. Among older patients in the 
HEHR database, 73% were female, and mean BMI (kg/m2) was 36 (84% had BMI 
≥ 30 and 56% BMI ≥ 35) with < 2% having BMI ≤ 25. In the HEHR database, 71% had 
dyslipidemia, 69% had hypertension, and 37% had type 2 diabetes mellitus. In addi-
tion, 90% were prescribed antihypertensive medications, 46% antidiabetic medica-
tions, and 26% antidepressants (including SSRIs and SNRIs). CONCLUSIONS: These 
data demonstrate consistencies between patient demographics, weight-related 
comorbidities, and concomitant medication use among older patients prescribed 
PHEN/TPM ER, subjects randomized in the CONQUER clinical trial, and the labeled 
indication. Over 18 months of PHEN/TPM ER use, medically appropriate individu-
als, including older patients, are utilizing PHEN/TPM ER as intended for chronic 
weight management.
etanercept monotherapy were analyzed. RESULTS: 100 eligible AS patient charts 
were abstracted; 44 on adalimumab (male:77%, mean age:36.4yrs, average months 
on adalimumab:27.2, 86% on 1st-biologic, 11% on 2nd-biologic) and 38 on etaner-
cept (male:82%, mean age:42.8 yrs, average months on etanercept:55.5, 89% on 
1st-biologic, 11% on 2nd-biologic). Top-5 comorbidites (adalimumab vs. etaner-
cept) were obesity: 18% vs. 13%, depression/anxiety: 11% vs. 5%, dyslipidemia: 
9% vs. 0%, heart disease: 2% vs. 5%, and other gastrointestinal: 5% vs. 3%. Among 
patients with available data, latest lab measures documented were (adalimumab 
vs. etanercept): ESR: 22.2mm/h vs. 20.4mm/h, CRP: 2.6mg/dl vs. 2.5mg/dl, and rheu-
matoid factor-positive: 2% vs. 3%. Latest disease severity measures documented 
were (adalimumab vs. etanercept): Swollen Joint Counts: 0.5 vs. 0.6, Tender Joint 
Counts: 1.0 vs. 0.8, HAQ: 0.8 vs. 0.3. CONCLUSIONS: Among AS patients, patients 
on adalimumab monotherapy were younger and on adalimumab for fewer aver-
age months than patients on etanercept. Most (> 85%) were on their first biologic. 
The adalimumab group appeared to have a slightly higher disease burden and 
comorbidities. Factors influencing the observed patterns (including the choice 
of specific biologic for targeted patient profiles) may warrant further scrutiny to 
optimize therapeutic interventions and improve outcomes.
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OBJECTIVES: Bleeding still a concern in surgical procedures and it is strong corre-
lated with post-operative complications and increased hospital costs. Fibrin Sealant 
is wide used for this purpose, there are several commercially available fibrin seal-
ants to reduce bleeding, but only one with the lack of bovine derivatives, which 
may, decreases the risk of allergic reaction. The aim of this study was to systematic 
review the safety and efficacy of aprotinin free hemostatic sealant for bleeding con-
trol. METHODS: The electronic databases PubMed, EMBASE, The Cochrane Central 
Register of Controlled Trials, Wiley and OVID, were reviewed. The date limit was 
set to December 31th of 2014. Only English literature was considered. The stud-
ies included were RCTs in surgical patients, the intervention being, aprotinin free 
hemostatic sealant, and the comparison, conventional hemostatic techniques. The 
primary outcome was to evaluated blood loss and time to achieve hemostatic and 
the second outcome was risk of blooding transfusion. RESULTS: 266 records were 
identified in all databases described, 17 records met the inclusion criteria. 15 stud-
ies (1492 patients) investigated the effect of intervention in several types of surgery 
for blooding loss, 12 out 15 studies observed less blood loss and time to achieve 
hemostatic with aprotinin free hemostatic sealant compared with conventional 
techniques. Four studies addressed the secondary outcome of this review, with 
169 patients. Three of them investigated the use of aprotinin free hemostatic in 
knee arthroplasty, and only one trial (58 patients) showed significant risk reduction 
compared with control group (RR 0.31 95% IC 0.13-0.74). One study investigated the 
intervention in Hip arthroplasty and did not found any significance. No adverse 
events were reported. CONCLUSIONS: Aprotinin free hemostatic sealant is a safety 
approach for bleeding control, promoting less blood loss and time to achieve hemo-
static. Risk of Blood transfusion needs further investigation.
PSY10
coMPaRative effectiveneSS and SafetY of aRgatRoban and 
bivaliRudin in PatientS with SuSPected hePaRin-induced 
thRoMbocYtoPenia
Patel V.A.1, Galanter W.L.1, Lee T.A.1, Schumock G.1, Nutescu E.A.1, Hohmann S.F.2, Walton S.M.1
1University of Illinois at Chicago, Chicago, IL, USA, 2University HealthSystem Consortium, 
Chicago, IL, USA
OBJECTIVES: Heparin-induced thrombocytopenia (HIT) is a prothrombotic condition 
that requires immediate treatment, usually with direct thrombin inhibitors (DTIs). 
However, the treatment may cause major bleeding. Data comparing the effective-
ness and safety of DTIs in the treatment of HIT is limited. Therefore, we compared 
the effectiveness and safety of two commonly used DTIs, argatroban and bivalirudin, 
in patients with suspected HIT in a real-world setting. METHODS: The Clinical 
Database/Resource Manager data from the UHC were used to identify hospitalized 
patients with suspected HIT discharged between 2009 to 2012. Using propensity 
scores, up to three argatroban-treated patients were matched to each bivalirudin-
treated patient. The rates of thrombosis, major bleeding, amputation and mortality 
were compared using hazard ratios (HRs) from Cox proportional hazard regression 
models. RESULTS: Of the 2,408 matched patients, 709 (29.4%) received bivalirudin 
and 1,699 (70.6%) received argatroban. Compared to bivalirudin, argatroban exhib-
ited a less harmful effect for major bleeding based on blood transfusion (6.1% vs. 
11.4%; P< 0.05). The result did not change when major bleeding was defined as blood 
transfusion with diagnostic codes. The risk of thrombosis (7.7% vs. 9.5%; P= 0.14), 
amputation (2.1% vs. 2.0%; P= 0.82) and mortality (24.2% vs. 25.5%; P= 0.49) were 
similar in argatroban-and bivalirudin-treated patients. CONCLUSIONS: Among 
patients with suspected HIT, the use of argatroban compared to bivalirudin was 
associated with a decreased risk of major bleeding but was similar for thrombosis, 
amputation and mortality risk.
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OBJECTIVES: In this study, the actual clinical use of antifungal drugs in patients 
who received hematopoietic stem cell transplantation (HSCT) was investigated 
using a Japanese healthcare database. We also aim to identify characteristics of 
